Please ensure Javascript is enabled for purposes of website accessibility

3 Reasons Rigel Pharmaceuticals Stock Can Continue Soaring

By Cory Renauer - Feb 21, 2021 at 7:21AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Here's why this stock's big run-up in recent months could be just the beginning.

Shares of Rigel Pharmaceuticals (RIGL -5.19%) recently popped after the company announced a collaboration deal with one of America's largest drugmakers, Eli Lilly (LLY 4.39%). Despite more than doubling over the past year, this underappreciated biotech stock could climb a lot further.

A new collaboration deal with a big pharmaceutical company isn't the only reason to keep an eye on this often overlooked biotech stock. Here's why investors can look forward to outstanding returns from Rigel Pharmaceuticals in the years to come.

Smiling scientist

Image source: Getty Images.

1. Eli Lilly's hungry for R552

On Feb. 18, 2021, Eli Lilly coughed up $125 million upfront to license R552 from Rigel Pharmaceuticals. This is a small molecule drug designed to inhibit RIPK1, a protein that regulates which cells get to survive and which ones need to be killed off.

So far, Rigel has presented results from a phase 1 study with healthy people that tried R552, but the company hasn't aimed it at any particular indication yet. While there are plenty of autoimmune disorders that could use better treatment options, Eli Lilly will most likely test R552 as a potential new Alzheimer's disease treatment.

Eli Lilly also agreed to a series of milestone payments that could reach $835 million if R552 goes on to become a highly successful drug. Rigel could also receive a royalty percentage in the high-teens from sales of R552, or less if the smaller biotech decides to let Eli Lilly pay for a higher percentage of development and commercialization costs.

2. Tavalisse sales for thrombocytopenia

Developing new treatments for Alzheimer's disease is an ultra-risky venture, but investors that buy shares of Rigel Pharmaceuticals don't need R552 to succeed to produce big gains. In 2018, the FDA approved Tavalisse to protect platelets in the bloodstream from destruction by their own immune systems for patients with a rare condition called chronic immune thrombocytopenia (cITP).

In 2020, sales of Tavalisse grew 41% year over year to $62 million as a treatment for cITP patients that respond poorly to standard care. Physicians are becoming more comfortable prescribing Rigel's first-in-class drug to cITP patients before they exhaust other available options, which could keep sales growing at this pace for years to come.

3. Tavalisse sales for COVID-19 and more  

In January, the U.S. Department of Defense awarded Rigel Pharmaceuticals $16.5 million to support an ongoing phase 3 trial testing Tavalisse as a treatment for hospitalized COVID-19 patients.

Severely ill COVID-19 patients often exhibit a hyperinflammatory response that includes the destruction of platelets and other critical blood components. We'll know more about Tavalisse's chance in this indication when a phase 2 study that began last year reads out results this spring.

Following encouraging mid-stage trial results, Rigel's also running a phase 3 trial with Tavalisse as a potential treatment for warm autoimmune hemolytic anemia (wAIHA). This is a rare disorder where patients' immune systems attack their own red blood cells and there aren't any treatments approved to treat wAIHA yet.

Scientist looking at numbers.

Image source: Getty Images.

Numbers ahead

Rigel Pharmaceuticals finished September with around $73 million in cash after losing about $14 million in the third quarter of 2020. Product sales have already caught up with selling, general, and administrative costs. By the end of 2021, Tavalisse sales will probably reach a level that covers the company's research and development outlay too.

Rigel's collaboration deal with Eli Lilly is a long shot because we still haven't seen evidence R552 provides a benefit for people with Alzheimer's disease or any other disorder. With Eli Lilly responsible for a majority of development costs, though, it's a long shot well worth taking.

While there's a good chance we'll never see huge milestone payments from Lilly, the upfront sum gives Rigel Pharmaceuticals enough cash to push Tavalisse forward at a much faster pace without subjecting shareholders to a dilutive secondary offering. 

Despite a clear path to profitability with Tavalisse, and a free shot at the Alzheimer's disease indication, Rigel Pharmaceuticals' market cap at recent prices is still less than $800 million. That's a lot less than you'd expect for a company approaching profitability within a few years of its first new drug launch. In fact, it's probably one of the best bargains in the biotech space right now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Rigel Pharmaceuticals, Inc. Stock Quote
Rigel Pharmaceuticals, Inc.
RIGL
$2.01 (-5.19%) $0.11
Eli Lilly and Company Stock Quote
Eli Lilly and Company
LLY
$298.85 (4.39%) $12.58

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/20/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.